Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells

Blood

Volumn 106, Issue 1, 2005, Pages 311-317

  Schubbert, Suzanne ^b   Lieuw, Kenneth ^b   Rowe, Sara L ^b   Lee, Connie M ^b   Li, XiaXin ^b   Loh, Mignon L ^b   Clapp, D Wade ^b   Shannon, Kevin M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR; INTERLEUKIN 3; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CELL MATURATION; COLONY FORMING UNIT GM; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; ERYTHROID CELL; GENE; GENE FUNCTION; GENE MUTATION; GERM LINE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA; LIQUID CULTURE; NOONAN SYNDROME; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTPN11 GENE; RISK ASSESSMENT;

EID: 22044452124     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-11-4207     Document Type: Article

References (41)

1. Barford D, Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure. 1998;6: 249-254.
2. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003;28:284-293.
3. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92:441-450.
4. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465-468.
5. Tartaglia M, KalidasK, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype- phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002; 70:1555-1563.
6. Bader-Meunier B, Tchernia G, Miélot F, et al. Occurrence of myeloproliferative disorder in patients with the Noonan syndrome. J Pediatr. 1997;130: 885-889.
7. Choong K, Freedman MH, Chitayat D, Kelly EN, Taylor G, Zipursky A. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol. 1999;21:523-527.
8. Side LE, Shannon KM. Myeloid disorders in infants with Noonan syndrome and a resident's "rule" recalled. J Pediatr. 1997;130:857-859.
9. Emanuel PD, Shannon KM, Castleberry RP. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today. 1996;2:468-475.
10. Arico M, Biondi A, Pui C-H. Juvenile myelomonocytic leukemia. Blood. 1997;90:479-488.
11. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in murine and human hematopoietic cells. Nat Genet. 1996;12: 144-148.
12. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte-macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia. Nat Genet. 1996;12:137-143.
13. Zhang Y, Vik, TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and Ras signaling in response to multiple cytokines. J Exp Med. 1998;187:1893-1902.
14. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004;103: 4243-4250.
15. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004;101:597-602.
16. Chan IT, Kutok JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004;113:528-538.
17. Miyauchi J, Asada M, Sasaki M, Tsunematsu Y, Kojima S, Mizutani S. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 1994;83:2248-2254.
18. ras. Blood. 1994;84:3435-3439.
19. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med. 1997;336:1713-1720.
20. Side L, Emanuel P, Taylor B, et al. Mutations of the NF1 gene in leukemias from children without evidence of neurofibromatosis, type 1. Blood. 1998;92:267-273.
21. O'Reilly AM, Pluskey S, Shoelson SE, Neel BG. Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol Cell Biol. 2000;20:299-311.
22. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34:148-150.
23. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103:2325-2331.
24. Tartaglia M, Niemeyer CM, Shannon KM, Loh ML. SHP-2 and myeloid malignancies. Curr Opin Hematol. 2004;11:44-50.
25. Tartaglia M, Martinelli S, Cazzaniga G, et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood. 2004;104:307-313.
26. Araki T, Mohi MG, Ismat FA, et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med. 2004;10:849-857.
27. Chan RJ, Leedy MB, Munugalavadla V, et al. Human somatic PTPN11 mutations induce hematopoietic cell hypersensitivity to granulocyte-macrophage colony stimulating factor. Blood. 2005;105: 3737-3742.
28. Mohi MG, Williams IR, Dearolf CR, et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell, 2005;7:179-191.
29. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138.
30. Birnbaum RA, O'Marcaigh A, Wardak Z, et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000;5:189-195.
31. -/- mice. Blood. 2004;104: 1204-1209.
32. Qu CK. Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim Biophys Acta. 2002;1592:297-301.
33. Bennett AM, Tang TL, Sugimoto S, Walsh CT, Neel BG. Protein-tyrosine- phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci U S A. 1994;91: 7335-7339.
34. Li W, Nishimura R, Kashishian A, et al. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol Cell Biol. 1994;14:509-517.
35. Yu WM, Hawley TS, Hawley RG, Qu CK. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene. 2003;22:5995-6004.
36. Bagley CJ, Woodcock JM, Stomski FC, Lopez AF. The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Blood. 1997;89:1471-1482.
37. Dorrell C, Takenaka K, Minden MD, Hawley RG, Dick JE. Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyl-transferase inhibition. Mol Cell Biol. 2004;24: 6993-7002.
38. Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG, Van Etten RA. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood. 2001;97:1442-1450.
39. Papayannopoulou T, Nakamoto B, Anagnou NP, Chui D, Dow L, Sanders J. Expression of embryonic globins by erythroid cells in juvenile chronic myelocytic leukemia. Blood. 1991;77:2569-2576.
40. Zhang J, Socolovsky M, Gross AW, Lodish HF. Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood. 2003;102:3938-3946.
41. Zhang J, Lodish HF. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors. Blood. 2004;104:1679-1687.